Overview
The 2020 Hachmo et al. trial from the Efrati lab is the first human study to demonstrate telomere elongation and senescent cell reduction via a therapeutic intervention. 35 adults aged 64+ underwent 60 HBOT sessions at 2.0 ATA; peripheral blood immune cells showed significant telomere lengthening and reduction in senescent T cells. The findings have generated significant interest in HBOT as a longevity intervention, though replication is pending.
Telomere length and senescent cell burden are two well-characterised biomarkers of cellular ageing. Shorter telomeres and higher senescent cell burden are associated with age-related disease and reduced healthspan. No pharmacological intervention has demonstrably elongated telomeres or reduced senescent cell burden in healthy humans.
The Hachmo et al. 2020 trial (Aging journal) is the first human study to do so with any intervention. 35 adults aged 64+ underwent 60 HBOT sessions at 2.0 ATA over 90 days. Peripheral blood lymphocytes showed significant telomere elongation (approximately 20% increase in some subsets) and reduction in senescent T cells. The magnitude of the biomarker changes exceeded what has been observed with any other intervention.
The findings are mechanistically plausible — HBOT-induced angiogenesis, HIF-1α effects, and oxidative stress signalling could plausibly influence telomere biology — but represent a single-centre single-arm trial. Replication is pending. The clinical significance of the biomarker changes (do they translate to healthspan or disease outcomes?) is also unclear and will take years of follow-up to establish.
Despite the preliminary nature of the evidence, longevity-focused HBOT has grown as a cash-pay market. Dedicated "longevity clinics" offer 60-session protocols at substantial cost ($10,000–$30,000). Patients should be aware the evidence remains preliminary.
How HBOT Works for This Condition
The Hachmo trial documented telomere elongation in peripheral blood immune cells and reduction in senescent T cells. Hypothesised mechanisms include HBOT-induced effects on telomerase activity, oxidative stress signalling, and anti-inflammatory effects on the senescence-associated secretory phenotype (SASP). The clinical significance of these cellular changes is unclear.
GRADE Evidence Rating
Hachmo 2020 (telomere length) is mechanistically interesting but clinical significance unclear. No hard-endpoint evidence.
| GRADE Domain | Assessment |
|---|---|
| Risk of bias | Moderate |
| Consistency | Single-centre |
| Directness | Indirect (surrogate endpoint) |
| Precision | Imprecise |
GRADE methodology: Grading of Recommendations Assessment, Development and Evaluation. See GRADE Working Group.
Clinical Protocol
| Typical protocol | 60 sessions at 2.0 ATA |
|---|---|
| Evidence level | Early single-arm trial — Novel finding, replication pending |
| FDA status | Not FDA-approved |
Hachmo protocol: 60 sessions at 2.0 ATA over 90 days (5 days per week), 90-minute sessions with air breaks.
Evidence Base
The Hachmo 2020 trial is the only published human study to date. Single-centre, single-arm, 35 participants. UHMS Tier 3 (investigational).
Cautions & Considerations
- Evidence is preliminary (single-centre single-arm trial).
- Clinical significance of biomarker changes is unclear.
- Substantial cost ($10,000–$30,000 for a full course) without insurance.
- Replication studies pending.
Key Research & References
- Hachmo et al. 2020 (Aging journal)
Indexed Studies for This Condition
Linked entries in the HBOT Studies Database.
Frequently Asked Questions
Will HBOT help me live longer?
There is no evidence that HBOT extends lifespan. The Hachmo trial documented biomarker changes (telomere, senescent cells) that are associated with healthier ageing, but did not demonstrate lifespan extension. Years of follow-up research will be required.
Is a longevity HBOT course worth $20,000?
The value judgement is personal. The evidence base is preliminary (single trial). Established lifestyle interventions (exercise, diet, sleep) have far stronger evidence and lower cost. Longevity HBOT is experimental.
What age is appropriate for longevity HBOT?
The Hachmo trial enrolled adults aged 64+. There is no evidence specifically supporting HBOT for anti-ageing in younger adults.
Research disclaimer: This article summarises published research for educational purposes only. Nothing here is medical advice. HBOT is a prescription medical treatment that must be administered under physician supervision in appropriately certified chambers. Discuss any treatment decisions with a qualified clinician.